Mukka Proteins Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
MUKKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mukka Proteins reported consolidated revenue from operations of Rs. 6,346.37 million for Q3 FY26, more than double the Rs. 2,962.04 million in Q3 FY25. For the nine months ended December 2025, revenue rose to Rs. 10,355.99 million from Rs. 6,077.64 million, a growth of about 70%. However, consolidated profit after tax for Q3 was Rs. 272.53 million, roughly flat versus Rs. 271.91 million a year ago, and the 9M PAT rose only modestly to Rs. 357.27 million, indicating sharp margin compression as costs and finance charges scaled faster than profits. Standalone results were weaker, with Q3 PAT of Rs. 187.59 million falling about 25% YoY. The board approved acquiring the remaining stakes in Ento Proteins and Haris Marine Products, making them wholly owned subsidiaries, and noted that a Vietnam acquisition has been pushed to June 2026. A customs department demand of Rs. 76.70 million was also disclosed as a contingent matter.
Strong top-line growth driven by acquisitions (United Gulf Fishery in Oman and Ocean Proteins becoming subsidiaries) is being offset by weaker margins and flat-to-declining profitability, which may weigh on near-term sentiment. Shareholders should watch margin trends and the pending Vietnam deal closure for earnings boost, while the new customs demand adds a small overhang.